EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The clinical terrain of immunotherapies in heterogeneous pancreatic cancer: unravelling challenges and opportunities

Melanie Herpels iD, Jun Ishihara, Anguraj Sadanandam iD

The Journal of Pathology · 2023

DOI: 10.1002/path.6171 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Pathology, 2023. Verfasst von Melanie Herpels und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Pathology, Institute of Cancer Research, London, UK. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 168 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is the most common and aggressive type of pancreatic cancer and has abysmal survival rates. In the past two decades, immunotherapeutic agents with success in other cancer types have gradually been trialled against PDACs at different stages of cancer progression, either as a monotherapy or in combination with chemotherapy. Unfortunately, to this day, chemotherapy still prolongs the survival rates the most and is prescribed in clinics despite the severe side effects in other cancer types. The low success rates of immunotherapy against PDAC have been attributed most frequently to its complex and multi‐faceted tumour microenvironment (TME) and low mutational burden. In this review, we give a comprehensive overview of the immunotherapies tested in PDAC clinical trials thus far, their limitations, and potential explanations for their failure. We also discuss the existing classification of heterogenous PDACs into cancer, cancer‐associated fibroblast, and immune subtypes and their potential opportunity in patient selection as a form of personalisation of PDAC immunotherapy. © 2023 The Pathological Society of Great Britain and Ireland.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalHumansImmunotherapyUnited KingdomTumor Microenvironment

Stichwörter der Autor:innen

cancer-associated fibroblastsclinical trialsimmune checkpoint inhibitorsimmunotherapyimmunotherapy failurepancreatic cancersubtypestumour microenvironment

Autor:innen und Institutionen

  • Division of Molecular Pathology, Institute of Cancer Research, London, UK.
  • Department of Bioengineering, Imperial College London, London, UK.
  • Centre for Global Oncology, Division of Molecular Pathology, Institute of Cancer Research, London, UK.
  • Centre for Translational Immunotherapy, Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK.

ORCID-Profile: Melanie Herpels, Anguraj Sadanandam

Zitieren

APA

Herpels, M., Ishihara, J., & Sadanandam, A. (2023). The clinical terrain of immunotherapies in heterogeneous pancreatic cancer: unravelling challenges and opportunities. The Journal of Pathology. https://doi.org/10.1002/path.6171

Vancouver

Herpels M, Ishihara J, Sadanandam A. The clinical terrain of immunotherapies in heterogeneous pancreatic cancer: unravelling challenges and opportunities. The Journal of Pathology. 2023. doi:10.1002/path.6171

BibTeX
@article{Herpels2023,
  author = {Herpels, Melanie and Ishihara, Jun and Sadanandam, Anguraj},
  title = {The clinical terrain of immunotherapies in heterogeneous pancreatic cancer: unravelling challenges and opportunities},
  journal = {The Journal of Pathology},
  year = {2023},
  doi = {10.1002/path.6171}
}
Kostenlos starten →